The Saudi Initiative for Asthma 2021 (SINA-2021) is the fifth version of asthma guidelines for the diagnosis and management of asthma for adults and children, which is developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged less than 5 years. SINA guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. Medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.


中文翻译：

---

沙特哮喘倡议 - 2021 年更新：成人和儿童哮喘诊断和治疗指南


2021年沙特哮喘倡议（SINA-2021）是第五版成人和儿童哮喘诊断和管理的哮喘指南，由沙特胸科学会附属机构SINA集团制定。SINA 的主要目标是为处理哮喘患者的医护人员提供最新、简单易懂且易于使用的指南。为了促进实现哮喘管理目标，SINA小组方法主要基于对成人和儿童的症状控制和风险评估。哮喘管理方法针对年龄组：成人、青少年、5-12 岁儿童和 5 岁以下儿童。新浪指南更注重个性化方法，反映了对疾病异质性的更好理解，整合了与生物制剂相关的建议、基于证据的治疗更新以及免疫治疗在管理中的作用。药物附录也已更新，添加了最新证据、现有药物的新适应症和新药物。该指南是根据现有证据、当地文献以及国家和地区层面的现状制定的。管理中还强调医患合作，其中还包括自我管理计划。